Skip to main content

Pay Bill Portals

Our Tests
Our Services
- - Oncology
    - - SERVICES
        
        NateraCore Services
        
        Pharma Partnership
    - - FOR PATIENTS
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
        
        Contact Us
    - - FOR CLINICIANS
        
        Schedule Session With Client Services
        
        Oncology Portal
        
        Order a Test Kit
        
        Contact Us
  - Organ Health
    - - SERVICES
        
        NateraCore Services
        
        ProReach
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Contact Us
    - - FOR CLINCIANS
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - SERVICES
        
        NateraCore Services
        
        Constellation
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
        
        Women’s Health Portal
        
        Contact Us
    - - FOR CLINICIANS
        
        Order Tests and Track Status on NateraConnect
        
        View Patient Results on NateraConnect
        
        Contact Us
Patient Resources
- - Oncology
    - - LEARN
        
        Signatera
        Altera
        Empower
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Organ Health
    - - LEARN
        
        Prospera
        Renasight
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule a Genetic Information Session
    - - CONNECT
        
        Contact Us
  - Women’s Health
    - - LEARN
        
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients)
        
        Pricing and Billing Information
        
        Women’s Health Portal
    - - CONNECT
        
        Contact Us
Clinical Resources
- - Oncology
    - - CLINICAL RESOURCES
        
        Order Forms
        
        Signatera
        Signatera Publications
        Altera
        Empower
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        Signatera Research Pipeline
        
        BESPOKE CRC
        
        BESPOKE IO
    - - CONNECT
        
        Oncology Portal
        
        Contact Us
  - Organ Health
    - - CLINICAL RESOURCES
        
        Organ Health Publications
        Prospera
        Renasight
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        ProActive Study
        
        PEDAL Study
        
        Trifecta Study
        
        MOTR Study
    - - CONNECT
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - CLINICAL RESOURCES
        
        Women’s Health Publications
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        Natera Academy Provider Education Hub
        View All Clinician Resources
    - - RESEARCH STUDIES
    - - CONNECT
        
        Contact Us
Company
Search for:
Pay Bill

Portals
Search for:

Natera, Inc.

- Altera
- Anora
- Empower
- Horizon
- Panorama
- Prospera
- Renasight
- Signatera
- Spectrum
- Vistara
- Blog
- Videos
- Brochure
- Whitepaper
- Manual
- Poster
- Report
- Study
- Webinars
- Natera Academy

Recent Searches

Home
Signatera
Feasibility of Personalized ctDNA Detection in Stage II and III Melanoma

Feasibility of Personalized ctDNA Detection in Stage II and III Melanoma

Brunsgaard EK, Bowles TL, Asare EA, et al. Melanoma Res. 2023

Previous Resource

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenari

Khaddour K, Zhou A, Butt OH, et al. Front. Oncol. 2022
Next Resource

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial

Cascone T, Kar G, Spicer JD, et al. Cancer Discov. 2023

Related Content

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Nederlof et al, Nature Medicine 2024

Read More
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases

Kataoka et al, Ann Oncol 2024

Read More
ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Nakamura, et al. Nature Medicine 2024

Read More
12 days ago
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Pr

Akaike T, Thakuria M, Silk AW, et al. J Clin Oncol. 2024

Read More
13 days ago
Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma

Hanna GJ, Dennis MJ, Scarfo N, et al., Clinical Cancer Research. 2024

Read More
about 2 months ago
Understanding the BESPOKE CRC Study: Your Path to Confident Cancer Monitoring

Read Article
3 months ago
ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

Watch Video
3 months ago
Signatera Bladder Cancer Brochure

Read More
3 months ago
Feasibility of Tumor-Informed Circulating Tumor DNA (ctDNA) for Molecular Residual Disease (MRD) Assessment in Pediatric Patients with Solid

Read More
3 months ago
Personalized circulating tumor (ct)DNA for monitoring disease status in head and neck squamous cell carcinoma

Read More
3 months ago
Longitudinal Analysis of Circulating Tumor DNA in Localized and Metastatic Urothelial Cancer

Read More
3 months ago
Association Between Circulating Tumor DNA and Recurrence-Free Survival in Patients with Resected Stage III Melanoma

Read More
3 months ago
A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari

Read More
3 months ago
Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca

Read More
3 months ago
Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s

Read More
3 months ago
Abstract # 518: ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1

Read More
3 months ago
Abstract 3598: Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosi

Read More
3 months ago
Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t

Read More
3 months ago
Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal j

Read More
3 months ago
Genomic alterations in early-onset versus average-onset stage IV colorectal cancer

Read More

Return to Resource Library

© Natera, Inc.

Our Tests
Our Services
Patient Resources
Clinical Resources
- Resource Library
- Provider Portals
Company
Contact

Natera Licenses
IT Security Compliance
Natera Notice of Data Collection for California Residents
Privacy Practices
Privacy Policy
Terms of Use
Sitemap

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.